drugset
drugset / Trial / NCT05901883

First-in-human, Single Ascending Dose Study of CEL383 in Healthy Adult Subjects

NCT05901883 ↗

Phase 1 Completed 48 enrolled Celsius Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of CEL383 in healthy volunteers.

Timeline

Start
2023-06-20
Primary completion
2024-01-17
Completion
2024-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject CEL383 Unknown — Intravenous

Indications

No indication recorded.